Holen Sie sich die Stockscreener-App
214.06
1.09%
2.30
Handel nachbörslich:
214.06
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt DHR?
Forum
Prognose
Aktiensplit
Dividendenhistorie
Schlusskurs vom Vortag:
$211.76
Offen:
$213.4
24-Stunden-Volumen:
3.89M
Relative Volume:
0.84
Marktkapitalisierung:
$150.48B
Einnahmen:
$24.78B
Nettoeinkommen (Verlust:
$3.68B
KGV:
41.37
EPS:
5.1743
Netto-Cashflow:
$5.29B
1W Leistung:
-4.65%
1M Leistung:
+1.98%
6M Leistung:
+12.00%
1J Leistung:
+1.77%
1-Tages-Spanne:
$211.98
$216.06
1-Wochen-Bereich:
$211.18
$228.38
52-Wochen-Spanne:
$160.93
$242.80
Danaher Corp Stock (DHR) Company Profile
Firmenname
Danaher Corp
Sektor
Branche
Telefon
(202) 828-0850
Adresse
2200 PENNSYLVANIA AVE. N.W., WASHINGTON, DC
Compare DHR vs TMO, NTRA, A, IQV
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
DHR
Danaher Corp
|
214.06 | 150.48B | 24.78B | 3.68B | 5.29B | 5.1743 |
TMO
Thermo Fisher Scientific Inc
|
654.80 | 241.26B | 45.20B | 6.87B | 6.75B | 18.19 |
NTRA
Natera Inc
|
410.35 | 59.47B | 2.50B | -226.32M | 71.51M | -1.6412 |
A
Agilent Technologies Inc
|
167.78 | 48.71B | 7.23B | 1.41B | 1.09B | 4.979 |
IQV
Iqvia Holdings Inc
|
258.21 | 44.50B | 16.63B | 1.39B | 2.12B | 8.0674 |
Danaher Corp Stock (DHR) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-12-09 | Eingeleitet | Goldman | Buy |
| 2025-12-02 | Eingeleitet | Morgan Stanley | Overweight |
| 2025-10-08 | Herabstufung | Rothschild & Co Redburn | Buy → Neutral |
| 2025-07-11 | Hochstufung | Scotiabank | Sector Perform → Sector Outperform |
| 2025-04-10 | Hochstufung | Barclays | Equal Weight → Overweight |
| 2025-03-21 | Hochstufung | Goldman | Neutral → Buy |
| 2025-03-14 | Hochstufung | Stifel | Hold → Buy |
| 2025-02-03 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2024-12-23 | Eingeleitet | Scotiabank | Sector Perform |
| 2024-12-19 | Eingeleitet | Guggenheim | Buy |
| 2024-12-13 | Hochstufung | BofA Securities | Neutral → Buy |
| 2024-10-31 | Hochstufung | Wolfe Research | Peer Perform → Outperform |
| 2024-10-01 | Eingeleitet | Stephens | Overweight |
| 2024-08-28 | Eingeleitet | Wells Fargo | Equal Weight |
| 2024-06-03 | Fortgesetzt | Jefferies | Buy |
| 2024-04-17 | Hochstufung | HSBC Securities | Hold → Buy |
| 2024-01-24 | Herabstufung | Barclays | Overweight → Equal Weight |
| 2023-12-18 | Eingeleitet | HSBC Securities | Hold |
| 2023-12-13 | Fortgesetzt | Wolfe Research | Peer Perform |
| 2023-12-07 | Herabstufung | Goldman | Buy → Neutral |
| 2023-07-19 | Eingeleitet | Raymond James | Outperform |
| 2023-05-01 | Eingeleitet | SVB Securities | Outperform |
| 2023-04-26 | Herabstufung | BofA Securities | Buy → Neutral |
| 2023-04-18 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2023-01-05 | Herabstufung | Credit Suisse | Outperform → Neutral |
| 2022-12-14 | Eingeleitet | Deutsche Bank | Buy |
| 2022-10-24 | Herabstufung | The Benchmark Company | Buy → Hold |
| 2022-08-25 | Eingeleitet | Credit Suisse | Outperform |
| 2022-08-17 | Fortgesetzt | Bernstein | Outperform |
| 2022-07-20 | Eingeleitet | UBS | Buy |
| 2022-06-01 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2022-04-25 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2022-01-11 | Eingeleitet | Bernstein | Outperform |
| 2021-10-15 | Fortgesetzt | Cowen | Outperform |
| 2021-09-10 | Bestätigt | BofA Securities | Buy |
| 2021-08-05 | Fortgesetzt | Credit Suisse | Outperform |
| 2021-07-23 | Bestätigt | Goldman | Buy |
| 2021-07-16 | Eingeleitet | The Benchmark Company | Buy |
| 2021-04-07 | Fortgesetzt | Robert W. Baird | Outperform |
| 2021-03-03 | Fortgesetzt | Barclays | Overweight |
| 2020-12-02 | Eingeleitet | Goldman | Buy |
| 2020-11-25 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2020-11-10 | Eingeleitet | KeyBanc Capital Markets | Overweight |
| 2020-06-16 | Hochstufung | Wolfe Research | Peer Perform → Outperform |
| 2020-04-02 | Herabstufung | Wolfe Research | Outperform → Peer Perform |
| 2020-03-26 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2020-02-03 | Bestätigt | Needham | Buy |
| 2020-01-08 | Eingeleitet | Wells Fargo | Overweight |
| 2020-01-07 | Eingeleitet | Citigroup | Buy |
| 2019-11-15 | Fortgesetzt | Stifel | Hold |
| 2019-10-28 | Bestätigt | Needham | Buy |
| 2019-10-14 | Fortgesetzt | Credit Suisse | Outperform |
| 2019-07-19 | Bestätigt | Needham | Buy |
| 2019-06-11 | Eingeleitet | Piper Jaffray | Neutral |
| 2019-05-30 | Eingeleitet | Wolfe Research | Outperform |
| 2019-04-17 | Bestätigt | Needham | Buy |
| 2019-02-28 | Bestätigt | Needham | Buy |
| 2019-02-25 | Hochstufung | Janney | Neutral → Buy |
| 2019-01-03 | Eingeleitet | Needham | Buy |
| 2018-04-20 | Bestätigt | Stifel | Buy |
Alle ansehen
Danaher Corp Aktie (DHR) Neueste Nachrichten
Danaher Corp. stock underperforms Thursday when compared to competitors - MarketWatch
Danaher stock after-hours at EUR 191.10: minus 2.35 percent - AD HOC NEWS
Danaher Corp Stock (DHR) Moved Down by 3.29% on Oct 1: What Investors Need To Know - TradingKey
Continuous Bioprocessing Technologies Market - GlobeNewswire Inc.
Danaher names Julie Sawyer Montgomery as president and CEO - Investing.com
Goldman Sachs raises target for Danaher stock to USD 250.00 - AD HOC NEWS
Guggenheim Raises Price Target on Danaher to $250 From $200, Keeps Buy Rating - marketscreener.com
What You Need to Know Ahead of Danaher’s Earnings Release - Yahoo Finance
Julie Sawyer Montgomery Assumes Role as Danaher President and Chief Executive Officer - Yahoo Finance
Danaher stock pre-market at EUR 196.30: plus 0.31 percent - AD HOC NEWS
Danaher Corp. stock underperforms Wednesday when compared to competitors - MarketWatch
A voluntary NYSE withdrawal covers Danaher (NYSE: DHR) 2.100% senior notes due 2026. - Stock Titan
DHR's Growth Backed by Strong Biotechnology Unit: Can It Maintain the Pace? - Yahoo Finance
Masimo Wins Two OCTANE High Tech AwardsCompany Recognized for 'Deal of the Year' and 'Best Technology Leadership Team' - PR Newswire
Danaher stock trades at EUR 198.48 ahead of October 21 results - AD HOC NEWS
Danaher stock after-hours at EUR 198.88: minus 0.10 percent versus the Lang & Schwarz prior close - AD HOC NEWS
Leica Biosystems Completes Acquisition of StatLab to Bolster Delivery of More Precise, Timely Diagnostics for Cancer Patients - marketscreener.com
Leica Biosystems Acquires StatLab From Linden Capital And Audax Private Equity - Pulse 2.0
Danaher stock reports USD 6.26 billion Q2 revenue ahead of earnings - AD HOC NEWS
Danaher stock at USD 224.49 on September 25, 2026 - AD HOC NEWS
Gilead vs. Danaher: Which Healthcare Growth Story is More Convincing? - Yahoo Finance
Danaher Corp Agencies, 2024 - OpenSecrets
Global Therapeutic Drug Monitoring Consumables Market Forecast, 2026-2032 - GlobeNewswire Inc.
Danaher Corp Lobbyists, 2024 - OpenSecrets
Danaher Corp Lobbyists, 2022 - OpenSecrets
Danaher Corp. stock slips before the bell - AD HOC NEWS
What Does Veralto's (NYSE:VLTO) Dividend and Climate Validation Signal? - Kalkine Media
Danaher Corporation stock sets October earnings date - AD HOC NEWS
DHR|Danaher Corp|Price:227.330|Chg%:+2.840 - TradingKey
Danaher stock heads into the open after a 2.43 percent gain - AD HOC NEWS
Danaher stock ends the day 2.43 percent higher at USD 221.09 - AD HOC NEWS
Danaher (DHR) Stock Looks Reasonable On Label Free Detection Growth - Yahoo Finance
Danaher Corp. stock holds near USD 200 before October results - AD HOC NEWS
Danaher (DHR) Institutional Ownership 2026 $DHR - MarketBeat
Danaher stock rises 0.16 percent ahead of the open - AD HOC NEWS
Automated Microscopy Market Advances as AI-Powered Image Analysis Transforms Digital Pathology and Semiconductor Inspection - GlobeNewswire Inc.
Danaher stock rises 2.38 percent after the close - ad-hoc-news.de
Danaher Corp. stock outperforms competitors on strong trading day - MarketWatch
Danaher Schedules Third Quarter 2026 Earnings Conference Call - marketscreener.com
Danaher will webcast its next financial update Oct. 21 - Stock Titan
Danaher Corp. stock gains as valuation stays above fair value - AD HOC NEWS
Danaher Corp. stock gains 1.97 percent ahead of the open - AD HOC NEWS
Danaher stock ends the day 1.97 percent higher at the close - AD HOC NEWS
Danaher stock holds steady as reduced growth outlook tempers sentiment - AD HOC NEWS
Goldman Sachs Adjusts Price Target on Danaher to $250 From $210, Maintains Buy Rating - marketscreener.com
Danaher stock heads into the open after a modest loss - AD HOC NEWS
Danaher Corp. stock gains after UBS starts coverage with USD 250 target - AD HOC NEWS
Danaher stock gains after UBS starts coverage at USD 250 - AD HOC NEWS
Why Is Danaher (DHR) Drawing Fresh Attention? - Kalkine Media
Cardinal Health (NYSE:CAH) Vs Danaher Corporation (NYSE:DHR) – Here’s The One Jim Cramer Said Did Better - Yahoo Finance
A new gene-editing tool is designed to reduce off-target edits - Stock Titan
Finanzdaten der Danaher Corp-Aktie (DHR)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.46%
0.96%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):